The life sciences industry is facing unprecedented revenue headwinds, expecting a $1 trillion–$1.5 trillion loss over the next decade due to the Inflation Reduction Act (CMS price negotiations for Medicare), an accelerating patent cliff, and the end of the blockbuster regime. The inflection point here will see new opportunities, with AI playing a decisive role in drug discovery, supply chain, and market access. As life science enterprises reevaluate their strategies, products, and commercial models, suppliers must play a different role—one of partnership rather than a subservient service provider.
The ”HFS Horizons: Life sciences service providers, 2025” report evaluates 41 service providers on their ability to impact the quadruple aim of care: cost, experience, health outcomes, and health equity. It covers their capabilities and outcomes across the HFS life sciences value chain to understand the why, what, how, and so what of their offerings, with a focus on industry-specific capabilities rather than horizontal IT or BPS services.
The study examines service providers’ maturity across three distinct Horizons:
The report highlights each provider’s placement, strengths, and development opportunities across these Horizons. It is global in scope and offers actionable insights for life sciences enterprises, service providers, and ecosystem partners that are shaping the future of healthcare innovation.

Note: All service providers within a Horizon are listed alphabetically
Source: HFS Research, 2025
To read the rest of the research, click the download button below.
Register now for immediate access of HFS' research, data and forward looking trends.
Get StartedIf you don't have an account, Register here |
Register now for immediate access of HFS' research, data and forward looking trends.
Get StartedError: Contact form not found.